When is a bubble not a bubble but a fundamental and lasting shift in investor sentiment towards a sector? Despite repeated calls from the biotech bear camp that the end is in sight for the continued optimism enjoyed by the sector we continue to enjoy a burst of IPOs, fundraisings and M&A deals.
03 Aug 2015
Life Sciences Review - The Biotech Feast - after the party comes the hangover
Eden Research, 7.9 | Motif Bio, 0.1 | Tiziana Life Sciences, 24.5 | Scientific Digital Imaging, 60.5 | Genedrive, 9.0 | ImmuPharma, 12.5 | SYNERGY HEALTH PLC, 0 | Benchmark, 34.5 | Advanced Oncotherapy, 34.5 | Avacta Group, 21.8
-
-
-
Derren Nathan
-
10 pages
-
.png)
